Roy M Gulick Selected Research

efavirenz (Sustiva)

1/2018	Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.
1/2017	Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.
2/2015	Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.
7/2014	Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.
12/2012	Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
11/2011	Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
1/2011	Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants.
9/2010	Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.
3/2010	Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
3/2010	Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roy M Gulick Research Topics

Disease

38	Acquired Immunodeficiency Syndrome (AIDS) 01/2021 - 07/2002
19	Infections 01/2019 - 01/2002
18	HIV Infections (HIV Infection) 10/2022 - 01/2002
4	COVID-19 10/2022 - 01/2020
4	Viremia 01/2019 - 11/2003
3	Disease Progression 05/2011 - 03/2007
2	Diarrhea 01/2020 - 01/2008
2	Hepatitis B 01/2018 - 12/2005
2	Insulin Resistance 05/2011 - 04/2007
2	Sexually Transmitted Diseases (Sexually Transmitted Disease) 11/2006 - 01/2002
1	Coronavirus Infections 10/2022
1	Injection Site Reaction 12/2021
1	Rheumatic Diseases (Rheumatism) 01/2021
1	Thrombosis (Thrombus) 01/2021
1	Vomiting 01/2020
1	Drug-Related Side Effects and Adverse Reactions 01/2019
1	Aspergillosis 09/2016
1	Sinusitis 09/2016
1	Hepatitis C 12/2013
1	Cardiovascular Diseases (Cardiovascular Disease) 05/2011
1	Virus Diseases (Viral Diseases) 12/2010
1	Tuberculosis (Tuberculoses) 07/2010
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2010
1	Proteinuria 08/2009
1	Epstein-Barr Virus Infections 03/2009
1	Lymphoma (Lymphomas) 03/2009
1	Hodgkin Disease (Hodgkin's Disease) 03/2009
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2009
1	Nausea 01/2008
1	Abdominal Pain (Pain, Abdominal) 01/2008
1	Neoplasms (Cancer) 07/2007

Drug/Important Bio-Agent (IBA)

19	efavirenz (Sustiva)FDA Link 01/2018 - 04/2004
14	Pharmaceutical PreparationsIBA 10/2022 - 01/2002
10	RNA (Ribonucleic Acid)IBA 01/2019 - 08/2006
7	Maraviroc FDA Link 01/2022 - 10/2008
7	NucleosidesIBA 01/2020 - 07/2002
7	Lamivudine (Epivir)FDA Link 01/2019 - 07/2002
6	abacavir (Ziagen)FDA Link 02/2015 - 04/2004
6	vicrivirocIBA 08/2010 - 02/2007
5	Reverse Transcriptase InhibitorsIBA 01/2020 - 04/2004
4	Zidovudine (Retrovir)FDA LinkGeneric 04/2007 - 07/2002
3	Tenofovir (Viread)FDA Link 01/2022 - 02/2019
3	Emtricitabine (Emtriva)FDA Link 01/2022 - 02/2019
3	Protease Inhibitors (Protease Inhibitor)IBA 01/2020 - 04/2004
3	dolutegravirIBA 01/2019 - 03/2016
3	AntibodiesIBA 11/2018 - 01/2015
3	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 03/2009
3	Saquinavir (Invirase)FDA Link 11/2005 - 09/2002
3	Indinavir (Crixivan)FDA Link 04/2004 - 09/2002
2	IntegrasesIBA 12/2021 - 01/2018
2	RacivirIBA 12/2021 - 01/2018
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2021 - 01/2020
2	Raltegravir Potassium FDA Link 02/2019 - 04/2009
2	Ritonavir (Norvir)FDA Link 02/2019 - 04/2004
2	Anti-Retroviral Agents (Antiretroviral Agents)IBA 11/2018 - 06/2004
2	Cytochrome P-450 CYP2B6 (CYP2B6)IBA 12/2012 - 09/2010
2	LipidsIBA 05/2011 - 04/2007
2	HDL CholesterolIBA 04/2007 - 12/2005
1	lopinavir-ritonavir drug combination (Kaletra)FDA Link 10/2022
1	cabotegravirIBA 12/2021
1	theasinensin AIBA 01/2021
1	Thromboplastin (Tissue Factor)IBA 01/2021
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021
1	Prothrombin (Factor II)IBA 01/2021
1	Integrase InhibitorsIBA 01/2020
1	Darunavir (Prezista)FDA Link 02/2019
1	Illicit Drugs (Recreational Drugs)IBA 02/2019
1	Atazanavir Sulfate (Reyataz)FDA Link 02/2019
1	fibrin fragment D (D-dimer)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	boldenone undecylenate (Equipoise)IBA 01/2019
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2018
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2018
1	Peptide Hydrolases (Proteases)FDA Link 01/2018
1	Phosphotransferases (Kinase)IBA 01/2018
1	Polysaccharides (Glycans)IBA 02/2017
1	Immunologic Factors (Immunomodulators)IBA 09/2016
1	Lopinavir FDA Link 11/2011
1	C-Reactive ProteinIBA 05/2011
1	Amino Acids FDA Link 12/2010
1	Proteins (Proteins, Gene)FDA Link 12/2010
1	Peptides (Polypeptides)IBA 12/2010
1	HLA Antigens (Human Leukocyte Antigens)IBA 12/2010
1	Cytochrome P-450 CYP3AIBA 09/2010
1	Nevirapine (Viramune)FDA Link 03/2010
1	CreatinineIBA 08/2009
1	AntigensIBA 03/2009
1	oxidized low density lipoproteinIBA 04/2007
1	Triglycerides (Triacylglycerol)IBA 04/2007
1	LDL CholesterolIBA 04/2007
1	Glucose (Dextrose)FDA LinkGeneric 04/2007
1	CholesterolIBA 04/2007
1	ChemokinesIBA 02/2007

Therapy/Procedure

18	Therapeutics 01/2021 - 01/2002
6	Art Therapy 11/2018 - 06/2004
2	Salvage Therapy 09/2002 - 01/2002
1	Injections 12/2021
1	Immunotherapy 01/2015
1	Aftercare (After-Treatment) 02/2006